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INTRODUCTION
Serum appearance of p53 antibodies can be appreciated as a
similarly identified aspect of p53 gene mutations (1, 2), and its
significance as an indicator of progressive potential of the tumors
has been reported in some human malignant tumors including
breast cancer (2, 3).
We also recently reported the close correlation of serum appear-
ance of p53 antibodies with an incidence of triple negative breast
cancer that is well known to be correlated with more malignant
potential of the tumor causing worse outcome of the patients (2).
Moreover we have proposed a newly devised criteria based on
the incidence of triple negative breast cancer and nuclear grade to
predict tumor recurrence of invasive ductal carcinoma of the breast
(4).
In this study, we investigated to find out a further evidence to
demonstrate the significance of serum appearance of p53Ab as an
indicator of progressive potential in invasive ductal carcinoma
(IDC) of the breast.
PATIENTS AND METHODS
Patients
One hundred and twenty nine women with breast IDC, who had
been treated with surgical resection between April 2008 and October
2013 in our institute, were studied in the current study. This study
was approved by the institutional ethic committee of Fukuoka
Higashi Medical Center.
Pathologic investigation
Pathological features were presented according to the general
rules for clinical and pathological recording of breast cancer estab-
lished by the Japanese Breast Cancer Society (5) and TNM classifica-
tion of malignant tumors prescribed by the International Union
Against Cancer (6).
Triple negative breast cancer (TNBC)
Expression of estrogen receptor (ER), Progesterone receptor
(PgR), and human epidermal growth factor receptor 2 (HER2)
were examined using an usual immunohistochemical methods and
an additional FISH examination was performed to find out HER2
expression for cases with an immunohistochemical expression of
HER2 2+. Then, tumors which are found to be absolutely negative
for expression of hormone receptors (ERand PgR) and HER2
could be diagnosed as TNBC.
Definition of nuclear grade
Nuclear grade (NG) was determined as an aggregate of nuclear
atypia score and mitotic count score according to the criteria was
shown in Table 1 (7).
Determination of TGS (Triple negative cancer and nuclear grade 3
score)
Definition of TGS was shown in the previous report (4). In
brief, patients who had both pathological characteristics of TNBC
and NG 3 were allocated a TGS 2. Patients who had one of these
characteristics were allocated a TGS 1, and patients who had none
were allocated a TGS0.
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Assayof serumanti-p53antibodies
Serum were drawn from the patients preoperatively and serum
anti -p53 antibodies (p53Abs) were assessed by an enzyme-linked im-
munoabsorbent assay (ELISA) using anti -p53 EIA kit II (MESACUP
anti -p53 test (Medical and Biological Laboratories Co., Ltd, Nagoya,
Japan)(8). The samples were added to the wells of a microtiter plate
coated with either wild- type human p53 or the control protein and
then they were incubated for 60 minutes at 37. After washing with
the washing solution, goat anti -human immunoglobulin (IgG) anti-
body conjugated with peroxidase was added and incubated for 60
minutes at 37. Next, the subtrate solution was added and incu-
bated for 10 minutes. After adding the stop solution, light absorp-
tion was measured at the length of 450 nm using the photospec-
trometer. When the optic density was more than the lowest positive
control samples, the samples were considered positive for p53Abs.
Then the standard sample was diluted in various concentrations
and the light absorption was measured in the same way. A calibra-
tion curve was constructed from the specific signals of the standard
samples, then the level of p53Abs was measured using the calibra-
tion curve. According to the manufacture, patients with serum con-
centration of more than 1.30 U/mL was regarded to have a serum
appearance of p53Abs.
Statistical analysis
Then, correlation of the serum appearance of p53Abs with
clinicopathologic factors including TGS values were examined.
Values were expressed meanSEM. The Fisher’s exact test and
non-parametric test (Mann-Whitney U test) were used to compare
the clinicopathologic data. A P value of less than 0.05 was consid-
ered significant.
RESULTS
p53Abs was detected in 11.6% (15 out of 129) of the sera of pa-
tients with breast IDC. Relationship between serum appearance
of p53Abs and clinicopathologic characteristics were demon-
strated in Table 2. No significant difference was observed regard-
ing the age, menstruation, operative procedures, histologic type,
size of the tumors, lymph node metastasis and the tumor stage.
There was a significant correlation between appearance of p53Abs
and recurrence of the tumors (P = 0.035).
Correlation of serum appearance of p53Abs with expression of
hormonal receptor, ER and PgR, and HER2, incidence of TNBC,
NG, and TGS was shown in Table 3. Significant correlation of
serum appearance of p53Abs with negative expression of ER (P =
0.011). The proportion of TNBC was significantly higher among
patients with serum appearance of p53Abs (P = 0.013). There was
also a significant correlation between serum appearance of p53Abs
and NG (P = 0.017). Moreover a significant correlation was ob-
served between serum appearance of p53Abs and TGS (P = 0.0005).
DISCUSSION
The p53 protein accumulation in tumor cells can be recog-
nized in many human tumors (9), and this accumulation of the muta-
tional p53 can subsequently induce serum circulating anti -p53
antibodies (p53Abs) as the results of the immunological response
to p53 (10). On the other hand, in a previous investigation (11), it
was mentioned that while a development of p53 antibodies in sera
of patients with malignant tumors is derived from the type of p53
gene mutation, p53 accumulation and/or p53 gene mutation does
Table1. Decision of nuclear grade
Nuclear grade is decided by the sum of the nuclear atypia score and the
mitotic counts score that are defined as follows.
Grade 1 : 2 or 3 points
Grade 2 : 4 points
Grade 3 : 5 or 6 points
Nuclear atypia score
Score 1 : Nuclei are relatively uniform in size and shape, and chro-
matin in inconspicuous.
Score 2 : Intermediate between 1 and 3
Score 3 : There is considerable variation in size and shape of nuclei and
the increase and unevenness of chromatin, sometimes hav-
ing giant nucleoli.
Mitotic counts score
After selecting the area in which mitoses are most abundant by small or
intermediate magnification, the mitoses are counted on larger magnifica-
tion. When using a 20 mm field of view, count 10 high-powerfields (40x
objective).
Score 1 : 0 -4 mitoses
Score 2 : 5 -10 mitoses
Score 3 : 11 or more than 11 mitoses
Table 2. Correlation of serum appearance of anti -p53 antibody with
clinicopathological features
p53Abs
Positive
(n=15)
p53Abs
negative
(n=114)
P value
Age 59.517.8 62.413.0 0.424
Menstruation
Pre-menopausal
Post -menopausal
5(33.3)
10(66.7)
20(17.5)
94(82.5)
0.146
Operation
Conservation
Mastectomy
11(73.3)
4(26.7)
76(66.7)
38(33.3)
0.687
Histology
Papillo - tubular
Solid - tubular
Scirrhous
Others
5(33.3)
6(40.0)
1(6.7)
3(20.0)
54(47.4)
20(17.5)
33(28.9)
7(6.2)
0.062
T factor
T1
T2
T3
8(53.3)
7(46.7)
0
72(63.2)
38(33.3)
4(3.5)
0.553
Lymph node metastasis
Positive
Negative
3(20.0)
12(80.0)
28(24.6)
86(75.4)
0.802
Tumor stage
I
IIA
IIB
III
8(53.3)
5(33.3)
0
2(13.3)
64(56.1)
27(23.7)
16(14.0)
7(6.2)
0.308
Tumor recurrence
Yes
No
3(20.0)
12(80.0)
6(5.3)
108(94.7)
0.035
p53Abs : anti -p53 antibody
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not always result in an immune response of p53.
However, in our previous report, a significantly close correlation
of serum p53Abs with an immunohistochemical p53 overexpres-
sion in the breast cancer tissues was demonstrated (2).
Proportion of serum appearance of p53Abs in patients with
breast IDC in this study was found to be some 12%, and this re-
mains in the range of the values reported in the previous study
showing from 9% to 22% (2, 3, 12-14).
Serum appearance of p53Abs has been reported to be found in
patients bearing with even early stage breast cancer whereas it can
not be detected in patients with benign tumor, indicating that se-
rum appearance of p53Abs can possibly be a biological marker for
an appropriate detection of breast cancer (15).
Moreover previous reports demonstrated that serum appearance
of p53Abs could be indicator for progressive potential of breast
cancer, including more frequent incidence for axillary lymph node
metastasis and larger sizeof the breast tumors, more unfavorable
prognosis of the patients (16), less favorable effectiveness derived
from anthracycline-based chemotherapy for the tumors (17), and
higher incidence of the pathological triple negative breast cancer
(TNBC), that are absolutely negative for expression of hormone
receptors (ER and PgR) and HER2 and is known to have a more
aggressive potential compared with other pathological type of
breast IDC (2, 3).
Based on well known knowledge that pathological nuclear grade
(NG) has been considered to show a cellular proliferation poten-
tial of breast cancer (18) in addition to the incidence of TNBC with
more aggressive potential of breast cancer (19, 20), we recently
suggested a cumulative scoring system (TGS) as a newly devised
criteria to predict tumor recurrence and outcome of the patients
with IDC by combination of NC and the incidence of TNBC with the
results that TGS could classify prognosis and time to progression of
the patients with breast IDC with a preferable stratification (4).
In the current study, although no significant correlation was
found between serum appearance of p53Abs and such pathologic
factors as incidence of lymph node metastasis and tumor size (T
factor), serum appearance of p53Abs was significantly correlated
with NG 3, incidence of TNBC and also with TGS score. Moreover,
tumor recurrence was found to be significantly higher among pa-
tients with serum appearance of p53Abs. On the other hand, no
significant correlation of such pathologic factors regarding malig-
nant potential of breast IDC as NG, TNBC, and TGS with serum
elevation of such tumor markers as CEA and CA15-3 (data not
shown).
TGS was constructed by two well -known prominent indicators
of malignant potential of breast cancer of an incidence of triple
negative cancer and nuclear grade of the tumor. And moreover the
fact that TGS could be significantly correlated with serum appear-
ance of p53Abs can compensate for the further clinical signifi-
cance of serum appearance of p53Abs as an indicator of malignant
potential of breast cancer.
The data regarding malignant potential of the tumor by measur-
ing serum p53Abs can be brought about anytime while such pa-
thologic factors as TNBC and NG would be definitively obtained at
the timing of surgical treatment. Moreover one another advan-
tage in measuring serum p53Abs is possibly to acquire the more
objective and reproducible data. These might be helpful to both
patients with breast IDC and physicians.
In conclusion, serum appearance of anti -p53 antibody, that can
be easily measured, would be utilized to predict malignant po-
tential of breast IDC.
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